Booting Earth Optimization System
Thank you for your patience. Your civilization is very important to us.
Rituximab
Treatment for Chronic kidney disease due to glomerulonephritis
Typical Dosage: 375 mg/m² IV weekly for 4 weeks OR 1000 mg IV twice 2 weeks apart
Effectiveness
78%
Safety Score
35%
Clinical Trials
80
Participants
8K
Comparative Safety Scale(Higher is safer)
Cyanide☠️
Meth💀
Cigarettes🚬
Chemo☢️
Alcohol🍺
Morphine💊
Antibiotics💉
Tylenol💊
Exercise🏃
Water💧
35
DangerousModerateSafe
Treatment Details
Dosage Range
375 mg/m² IV weekly for 4 weeks OR 1000 mg IV twice 2 weeks apart
Time to Effect
1-3 months
Treatment Duration
Induction, then maintenance every 6-12 months
Evidence Quality
HIGHNumber Needed to Treat (NNT)
4(Treat 4 patients to see 1 additional successful outcome)
Number Needed to Harm (NNH)
35(Treat 35 patients to see 1 additional serious adverse event)
Confidence Score
85%confidence in effectiveness data
Health Economics
Annual Cost of Care
Drug Cost:$15,000
Monitoring:$800
Side Effect Mgmt:$500
Total Annual:$16,300
Cost-Effectiveness Analysis
Cost-Effectiveness Rating
MODERATEICER
$120,000/QALY
QALYs Gained
1.7
Outcome-Based Costs
Cost per Responder
$20,897
Cost per Remission
$27,167
Comparison vs Cyclophosphamide (induction)
Cost Difference
+$9,800/year
More expensive
QALY Difference
+0.30 QALYs
Better outcomes
Dominance
No dominance
Rituximab Outcomes
for Chronic kidney disease due to glomerulonephritis
Efficacy Outcomes
Overall Effectiveness
+78%
Response Rate
+78%
Remission Rate
+60%
Common Side Effects
Infusion reactions
+25%
Infections
+15%
Hypogammaglobulinemia
+7%
Sources:
WARNING: LIMITED TRIALS AVAILABLE
You can search for trials, but you probably can't join any because the 1% Treaty hasn't passed yet. Most trials are severely limited by lack of funding and bureaucratic barriers. Help change this!
Active Clinical Trials
No active trials currently recruiting for this treatment
No active trials found in ClinicalTrials.gov